hepatic fat — 19 things I got wrong before I got it right
Posting this as a discussion rather than a claim: hepatic fat — 19 things I got wrong before I got it right.
Went slowly because everything published describes a deliberate escalation. That is the extent of what I will say about it.
Assumed the weight numbers were the point and was corrected. They are secondary to what this is being developed for.
Sent a vial to Janoshik because there was nothing on file. 97.9% against a claimed 97.0%. First entry for this compound in my own log.
Research-use-only material is not approved for human use and nothing here should be read as a recommendation to use it.
best — the order this archive was captured in
It is a dual agonist at the GLP-1 and glucagon receptors. The glucagon arm is associated with increased energy expenditure and with effects on hepatic fat, which is why the development programme is oriented towards liver disease.
It is a dual agonist at the GLP-1 and glucagon receptors.
Disagreeing with this bit: that number comes from a different programme with a different population.
Careful with the mechanism claim. Glucagon agonism is plausible as an explanation and it has not been isolated as the operative one.
Independent result logged. There are almost none for this compound, so it is genuinely valuable.
the hepatic data is what makes this compound different from the others
independent testing on this compound is very thin
Spent an evening on the histology scoring system and understood the trial literature far better afterwards.
the weight numbers are secondary to what this is being developed for
Histological endpoints in this field are scored on biopsy: resolution of steatohepatitis without worsening of fibrosis, or improvement in fibrosis without worsening of steatohepatitis. Both are harder to achieve and to interpret than an imaging surrogate.
this board is small because the compound is early
Nothing containing this compound is approved anywhere. Research-use-only material is not approved for human use.
Nothing containing this compound is approved anywhere.
This is the framing the board needs. It is a hepatic programme first.
research material is not approved for human use, which is why the clinical record here is thin
Looked for independent results across this whole site and found almost none. Worth knowing before forming an opinion.
What does the tolerability table say at that dose?
do not import intuitions from the obesity programmes
Is that a weight number from a different programme?
That is an escalation schedule for an unapproved compound and this board does not host those.
Imaging-derived liver fat fraction is a surrogate. It correlates with histology imperfectly, and a trial reporting one is not reporting the other.
- 1independent testing on this compound is very thin8 comments in this branch · started by u/tomas_lokken